Fig. 3

Caspase 1/4 inhibition with VX-765 limits CD4⁺T cell loss in HIS mice infected with HIV. HIS mice were selected for similar human immune system reconstitution and divided into two groups (n = 3/group). (A) Experimental design wherein both groups were administered rFLT-3 L (50ug in 250ul PBS, 0.2 mg/mL) on days 0, 4 and 8, and infected with HIV-1_ADA (10,000 ffu) on day 4. One group (HIV + VX) was treated with VX-765 via intraperitoneal injection on days 4–14 and one group (HIV control) was not treated. Blood, spleen, and LN were harvested on day 14 for analysis via flow cytometry. (B) Changes in human CD45⁺ leukocytes as a percent of total leukocytes and number of events in 100 ul of blood prior to HIV infection (d0) and at the end of study (d14) in HIV and HIV + VX groups. (C) Summarized flow cytometric analysis (mean ± SEM) demonstrating CD4⁺ cells as a percentage of human CD3⁺ T cells, and number of CD4⁺ cell events in the blood, spleen, and LN. Significant differences due to treatment were determined using an unpaired two-tailed Student’s T-test. **p < 0.01